Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 19, 2026

Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now?

View original at nasdaq.com
Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now? Key Points Lockheed Martin and Howmet Aerospace benefit from increased defense spending…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Howmet Aerospace is trading at more than 54 times forward earnings estimates, more than twice Lockheed's forward P/E ratio of 20.6, meaning much of Howmet's growth is already priced in

    60% confidence

  • Lockheed Martin's position as lead contractor for F-35 and major missile programs ensures steady cash flow largely insulated from traditional economic recessions

    60% confidence

  • The war in Iran will push Howmet's likely growth higher in 2026

    60% confidence

  • Lockheed Martin is a better buy than Howmet Aerospace due to steady income production, huge backlog, and greater diversity

    60% confidence

  • The Motley Fool Stock Advisor identified 10 best stocks for investors to buy now, and Lockheed Martin was not one of them

    60% confidence

Data points we hold from this source

Lockheed Martin Corporation · forward pe ratio20.6 ratio
Lockheed Martin Corporation · backlog194 USD
Lockheed Martin Corporation · quarterly dividend3.45 USD
Lockheed Martin Corporation · eps21.49 USD
Lockheed Martin Corporation · consecutive dividend increases23 years
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now? — Source | Via News | ViaNews EU